When looking for the best stocks to buy and watch, focus on those with rising relative price strength.
One stock that fits that bill is Sarepta Therapeutics stock, which had its Relative Strength (RS) Rating upgraded from 80 to 85 Thursday.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
IBD's unique RS Rating measures market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the last 52 weeks matches up against the rest of the market.
Decades of market research shows that the market's biggest winners often have an RS Rating of above 80 as they begin their biggest climbs.
Looking For Winning Stocks? Try This Simple Routine
Is Sarepta Therapeutics Stock A Buy?
The IBD 50 stock is in a buy range after climbing above an 85.15 buy point in a cup with handle. Once a stock moves 5% or higher beyond the original entry, it's considered out of a proper buy zone. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
Earnings grew 54% last quarter, up from 0% in the prior report. Revenue also increased, from 32% to 39%. Look for the next report on or around May 5.
Sarepta Therapeutics stock earns the No. 36 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharmaceutcls and Regeneron Pharmaceutical are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
